These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 28495513)
1. High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy. Urbanova L; Hradilova N; Moserova I; Vosahlikova S; Sadilkova L; Hensler M; Spisek R; Adkins I Immunol Lett; 2017 Jul; 187():27-34. PubMed ID: 28495513 [TBL] [Abstract][Full Text] [Related]
2. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172 [TBL] [Abstract][Full Text] [Related]
3. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Mikyšková R; Štěpánek I; Indrová M; Bieblová J; Šímová J; Truxová I; Moserová I; Fučíková J; Bartůňková J; Špíšek R; Reiniš M Int J Oncol; 2016 Mar; 48(3):953-64. PubMed ID: 26718011 [TBL] [Abstract][Full Text] [Related]
4. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype. Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024 [TBL] [Abstract][Full Text] [Related]
5. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Fucikova J; Moserova I; Truxova I; Hermanova I; Vancurova I; Partlova S; Fialova A; Sojka L; Cartron PF; Houska M; Rob L; Bartunkova J; Spisek R Int J Cancer; 2014 Sep; 135(5):1165-77. PubMed ID: 24500981 [TBL] [Abstract][Full Text] [Related]
6. High hydrostatic pressure in cancer immunotherapy and biomedicine. Adkins I; Hradilova N; Palata O; Sadilkova L; Palova-Jelinkova L; Spisek R Biotechnol Adv; 2018; 36(3):577-582. PubMed ID: 29409785 [TBL] [Abstract][Full Text] [Related]
7. Research and application of hydrostatic high pressure in tumor vaccines (Review). Yan S; Liu K; Mu L; Liu J; Tang W; Liu B Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760193 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988 [TBL] [Abstract][Full Text] [Related]
9. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
10. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. Salem ML Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701 [TBL] [Abstract][Full Text] [Related]
11. Effect of extracorporal high hydrostatic pressure on tumor cell adherence and viability. Diehl P; Reuning U; Gollwitzer H; Magdolen U; Gerdesmeyer L; Schauwecker J; Tuebel J; Gradinger R; Mittelmeier W; Schmitt M Oncol Rep; 2004 Aug; 12(2):369-73. PubMed ID: 15254704 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based immunotherapy. Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781 [TBL] [Abstract][Full Text] [Related]
13. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441 [TBL] [Abstract][Full Text] [Related]
14. Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy. Vavrova K; Vrabcova P; Filipp D; Bartunkova J; Horvath R Med Oncol; 2016 Dec; 33(12):136. PubMed ID: 27812850 [TBL] [Abstract][Full Text] [Related]
15. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects]. Rossowska J; Pajtasz-Piasecka E Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967 [TBL] [Abstract][Full Text] [Related]
16. Antigen trapping by dendritic cells for antitumor therapy. Pal C Methods Mol Biol; 2014; 1139():33-40. PubMed ID: 24619668 [TBL] [Abstract][Full Text] [Related]
17. High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. Weiss EM; Meister S; Janko C; Ebel N; Schlücker E; Meyer-Pittroff R; Fietkau R; Herrmann M; Gaipl US; Frey B J Immunotoxicol; 2010; 7(3):194-204. PubMed ID: 20205624 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cells for specific cancer immunotherapy. Meidenbauer N; Andreesen R; Mackensen A Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216 [TBL] [Abstract][Full Text] [Related]
19. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
20. Dendritic-tumor fusion cells in cancer immunotherapy. Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]